GC Genome지씨지놈

GC Genome's shares have roughly doubled over three months, while its trailing profit margins remain thin and its valuation is high.

GC Genome is a Korean clinical genomics firm offering over 300 genetic tests sold mainly to more than 1,000 hospitals and clinics in South Korea, with exports to partners in 22 countries. On trailing twelve-month figures to H1 2026 it reports revenue of ₩32.6B...

What stands out

• Trailing revenue is about ₩32.6B with an operating margin of 4.7%, up from 3.9% in 2025, but the data does not give revenue growth for the period.
• Trailing net income of ₩5.4B is much higher than operating income of ₩1.5B, so the net margin of 16.6% is likely boosted by items outside core operations; the data does not explain this.
• The shares closed at ₩10,040, up 92.3% over three months and 39.4% over one year, near the 52-week high of ₩10,480.
• At a P/E of 43.9 and P/B of 3.0, the stock trades well above the company's own DCF base value of ₩2,693 and above most listed peers in the data, though peer comparisons are limited to five companies.
• Cash of ₩37.1B exceeds reported borrowings, which are not given, and liabilities are 10% of equity; the stock pays no dividend.

What to watch

• The next quarterly or annual filings, to see whether revenue growth and operating margin continue to improve.
• Whether recent heavy retail selling of about ₩14.3B over 20 days (with institutions buying) continues, and the rise in foreign ownership from 2.9% to 4.3%.
• The gap between the share price and the DCF estimates (bear ₩2,265, bull ₩3,472), which depends on model assumptions.